- Stocks
- Pharma & Healthcare
- Vivanza Bio
Vivanza Bio share price
NSE: VIVANZAPharma & HealthcareDrug Manufacturers - Specialty & Generic
Vivanza Bio at a glance
With a market capitalisation of ₹7 Cr, it ranks 4001st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 9.0% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹6 Cr (+1,225.0% year on year) and net profit −₹0 Cr, on a consolidated basis. Promoters held 20.02% of the company as of 31 Mar 2026.
Key numbers
- Market cap
- ₹7 CrRank 4001 on NSE
- Price to book
- 1.62×FY26
- EPS (TTM)
- ₹0.10to Q4 FY26
- ROE
- 9.0%FY26
- ROCE
- 15.7%FY26
- Debt to equity
- 2.34FY26
- Net profit margin
- 0.3%FY26
- Book value / share
- ₹1.09FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Vivanza Bio quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹0 Cr | ₹9 Cr | ₹55 Cr | ₹45 Cr | ₹6 Cr |
| Revenue YoY | −73.6% | −60.6% | −77.1% | −89.1% | +266.4% | +1,745.3% | +2,916.7% | +1,225.0% |
| Net profit | ₹0 Cr | ₹0 Cr | ₹0 Cr | −₹1 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | −₹0 Cr |
| Net profit YoY | −44.9% | −92.3% | −81.0% | — | −66.7% | +2,700.0% | +400.0% | — |
| Net margin | 11.1% | 0.7% | 2.7% | −208.3% | 1.0% | 1.0% | 0.4% | −7.1% |
| EPS | ₹0.07 | ₹0.00 | ₹0.01 | −₹0.25 | ₹0.02 | ₹0.14 | ₹0.05 | −₹0.11 |
Vivanza Bio financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹10 Cr | ₹10 Cr | ₹18 Cr | ₹28 Cr | ₹7 Cr | — |
| Operating profit | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | −₹1 Cr | — |
| Net profit | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | −₹1 Cr | — |
| EPS (₹) | ₹0.00 | ₹1.00 | ₹2.00 | ₹0.00 | ₹0.00 | — |
| Cash from operations | −₹3 Cr | ₹0 Cr | −₹1 Cr | ₹2 Cr | −₹3 Cr | — |
| Total debt | ₹0 Cr | ₹3 Cr | ₹1 Cr | ₹3 Cr | ₹3 Cr | ₹1 Cr |
| Shareholders' equity | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr |
Vivanza Bio shareholding pattern
| Holder | 31 Dec 2024 | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 20.02% | 20.02% | 20.02% | 20.02% | 20.02% | 20.02% |
| Domestic institutions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Non-institutions | 79.98% | 79.98% | 79.98% | 79.98% | 79.98% | 79.98% |
Vivanza Bio vs peers
The listed Pharma & Healthcare companies nearest to Vivanza Bio by market capitalisation.
Ask anything about Vivanza Bio
Pivot answers on the live chart with evidence you can check, and tests strategies against VIVANZA's own history. Try: “Why has VIVANZA moved over the last three months?” · “Backtest a 50-day moving-average crossover on VIVANZA over five years” · “Compare VIVANZA with TRINITYLEA on margins and valuation”
Frequently asked questions about Vivanza Bio
What is the market cap of Vivanza Bio?
Vivanza Bio's market capitalisation is ₹7 Cr (₹7 Cr) at the 22 Oct 2026 close, ranking 4001st among the NSE companies Pivot tracks.
What is the ROE and ROCE of Vivanza Bio?
Return on equity was 9.0% in FY26 and return on capital employed was 15.7% in FY26 (consolidated figures).
Is Vivanza Bio a debt-free company?
No. Vivanza Bio's debt-to-equity ratio was 2.34 in FY26, with total debt of ₹1 Cr.
What were Vivanza Bio's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Vivanza Bio reported revenue of ₹6 Cr, +1,225.0% year on year, and net profit of −₹0 Cr.
What is the shareholding pattern of Vivanza Bio?
As of 31 Mar 2026: promoters 20.02%, domestic institutions 0.00%, non-institutions 79.98%.
Who are Vivanza Bio's competitors?
The listed Pharma & Healthcare companies closest to Vivanza Bio by market cap are Trinity League, Adline Chem Lab, Unjha Formula, Dr Lalchandani, DECIPHER LABS and Evoq Remedies.
Is Vivanza Bio a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Vivanza Bio's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VIVANZA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with V · all NSE stocks · this page as text